Rosen Law Firm Announces Class Action Lawsuit Against Spectrum Pharmaceuticals

Strategic Insights -

Spectrum Pharmaceuticals, a New York-based pharmaceutical company, has been hit with a class action lawsuit filed by the Rosen Law Firm, a global investor rights law firm. The lawsuit alleges that Spectrum made false or misleading statements to investors regarding its PINNACLE Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients. The lawsuit claims that investors suffered damages when the true details of the study entered the market. If you purchased Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.

Key Takeaways:

  • The Rosen Law Firm has filed a class action lawsuit against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) on behalf of purchasers of common stock between May 12, 2022, and September 22, 2022.
  • The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study and poziotinib, a drug intended to treat certain lung cancer patients.
  • The lawsuit claims that investors suffered damages when the true details of the study entered the market.
  • Investors who purchased Spectrum Pharmaceuticals common stock during the Class Period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
  • The lead plaintiff process was reopened by the Court, and if you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2025.
  • The Rosen Law Firm has a track record of success in securities class actions and shareholder derivative litigation, with over $438 million in recoveries for investors in 2019 alone.
  • The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors.

Statistics:

  • Over $438 million in recoveries for investors in 2019.
  • Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
  • Recovered hundreds of millions of dollars for investors since 2013.

Sources:

  • Newsfile Corp. - August 22, 2025
  • Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
  • Rosen Law Firm's website: https://rosenlegal.com